首页|Sunlenca?(Lenacapavir):A first-in-class,long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection

Sunlenca?(Lenacapavir):A first-in-class,long-acting HIV-1 capsid inhibitor for treating highly multidrug-resistant HIV-1 infection

扫码查看

LenacapavirCapsid inhibitorHIV-1 infectionHIV preventionMultidrug resistanceAntiretroviral medication

Chunhua Ma、Junbiao Chang、Bin Yu

展开 >

State Key Laboratory of Antiviral Drugs,Pingyuan Laboratory,NMPA Key Laboratory for Research and Evaluation of Innovative Drug,School of Chemistry and Chemical Engineering,Henan Normal University,Xinxiang,453007,China

College of Chemistry,Pingyuan Laboratory,State Key Laboratory of Antiviral Drugs,Zhengzhou University,Zhengzhou 450001,China

Tianjian Laboratory of Advanced Biomedical Sciences,Institute of Advanced Biomedical Sciences,Zhengzhou University,Zhengzhou 450000,China

2024

药学学报(英文版)

药学学报(英文版)

CSTPCD
ISSN:
年,卷(期):2024.14(12)